만성적 정신분열병 또는 분열정동장애를 가진 입원환자에서 Aripiprazole과 Haloperidol의 치료효과 및 안정성 비교：16주간의 임상적 연구의 결과
The Comparison of Efficacy and Safety between Aripiprazole and Haloperidol in the Treatment of Chronic Schizophrenia and Schizoaffective Disorder : Results from a 16-Week Clinical Study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives：The authors compared the efficacy and safety between aripiprazole and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Methods：This study was conducted in December, 2004 through April, 2007. We selected the subjects who were admitted to psychiatric clinic due to chronic schizophrenia or schizoaffective disorder as defined by DSM-IV criteria. The assessment of clinical symptoms was evaluated with PANSS before taking the drugs and every two weeks afterwards. The standard laboratory tests were also performed. The prolactin level was evaluated in every 4 weeks. Results：Total of 72 subjects were assigned either aripiprazole(N=33) or haloperidol(N=39) according to the admission order. There were no statistically significant differences on demographic variables. After 16-week study was completed, there were no statistically significant differences in positive, general and total score in PANSS except negative symptom. There were no significant differences among the variables related to metabolic syndrome except serum glucose and HDL cholesterol level between two groups. However, there was a significant difference in serum prolactin level. Conclusion：In the end, aripiprazole was generally good choice of treatment with less side effects, better tolerability than haloperidol. One, aripiprazole showed more improvements in negative, general and total PANSS subscales with no statistical significances except negative PANSS score. The other, the variables related to the metabolic syndrome need a further evaluation. And the last, aripiprazole yields more favorable serum prolactin level than haloperidol.
Abstract
Objectives：The authors compared the efficacy and safety between aripiprazole and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Methods：This study was conducted in December, 2004 through April, 2007. We selected the subjects who were admitted to psychiatric clinic due to chronic schizophrenia or schizoaffective disorder as defined by DSM-IV criteria. The assessment of clinical symptoms was evaluated with PANSS before taking the drugs and every two weeks afterwards. The standard laboratory tests were also performed. The prolactin level was evaluated in every 4 weeks. Results：Total of 72 subjects were assigned either aripiprazole(N=33) or haloperidol(N=39) according to the admission order. There were no statistically significant differences on demographic variables. After 16-week study was completed, there were no statistically significant differences in positive, general and total score in PANSS except negative symptom. There were no significant differences among the variables related to metabolic syndrome except serum glucose and HDL cholesterol level between two groups. However, there was a significant difference in serum prolactin level. Conclusion：In the end, aripiprazole was generally good choice of treatment with less side effects, better tolerability than haloperidol. One, aripiprazole showed more improvements in negative, general and total PANSS subscales with no statistical significances except negative PANSS score. The other, the variables related to the metabolic syndrome need a further evaluation. And the last, aripiprazole yields more favorable serum prolactin level than haloperidol.
참고문헌 (23)
- Travis MJ, "Aripiprazole in schizophrenia: consensus guidelines", Int J Clin Pract, 59(4), pp.485~495 (2005)
- John MK, "Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder", J Clin Psychiatry, 63, pp.763~771 (2002)
- Daniel EC, "Switching to aripiprazole from other antipsychotic agents: a multicenter randomized study", Psychopharmacology, 166, pp.391~399 (2003)
- Burris KD, "Aripiprazole, a novel antipsychotic, is a highaffinity partial agonist a human D2 dopamine receptors", J Pharmacol Exp Ther, 302, pp.381~389 (2002)
- Carson WH, "Aripiprazole vs. placebo in the treatment of chronic schizophrenia", Int J Neuropsychopharmacol, 5(1), pp.187~ (2002)
- Dixon L, "The association of medical comorbidity in shcizophrenia with poor physical and mental health", J Nerv Ment Dis, 187, pp.496~502 (1999)
- Defonzo RA, "Insulin resistance. A multifaceted syndrome responsible for NssIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease", Diabetes Care, 14, pp.173~194 (1991)
- Allison DB, "Antipsychotics-induced weight gain: a comprehensive research synthesis", Am J Psychiaty, 156, pp.1686~1696 (1999)
- Arranz B, "Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic naive first-episode schizophrenia patients", J Clin Psychiatry, 65, pp.1335~1342 (2004)
- Glennon RA, "Serotonin receptor subtypes. in: Psychopharmacology: The Fourth Generation of Progress", pp.419~ (1995), Raven Press
- Kurzthaler I, "The clinical implications of weight gain in schizophrenia", J Clin Psychiatry, 62, pp.32~37 (2001)
- butyloxy)-3,4-dihydro-2 (1H)-quinolinone(OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agpnistic activity and postsynaptic D2 receptor antoganist activity, "J Pharmacol Exp Ther", 1995, 329~336
- butyloxy)-3,4-dihydro-2(1H)-quinolinonw (OPC-14597) on prolactin release from the rat anterior piruitary gland, "J Pharmacol Exp Ther", 1996, 137~143
- Stahl SM, "Essential psychopharmacology. 3rd ed", pp.336~342 (2008), cambridge University Press
- "The Asia-Pacific perspective: redefining obesity and its treatment"[URL]
- Park HS, "Prevalence and associate factors with metabolic syndrome in South Korea from the korean National Health and Nutrition Examination Survey, 1998", J Korean Soc Study Obesity, 12, pp.1~14 (2004)
- Meyer J, "The metabolic syndrome and schizophrenia: a review", Int Rev Psychiatry, 17, pp.173~180 (2005)
- 남윤영, "만성 정신분열병 환자들의 대사증후군가 관련된 임상 특징들", 대한정신약물의학, 17, pp.335~341 (2006)
- Simpson JC, "Mortality among patients with schizophrenia", Schizophrenia Bull, 22, pp.485~499 (1996)
- Brown S, "Excess mortality of schizophrenia: a metaanalysis", Br J Psychiatry, 171, pp.502~208 (1997)
- 김양래, "Olanzapine을 투여 받은 정신분열병 환자의 체중, 체질량지수, 렙틴, 인슐린, 공복시 혈당의 변화", 신경정신의학, 40(6), pp.1240~1246 (2001), 대한신경정신의학회
- Melkersson KI, "Insulin and leptin levels in patients with schizophrenia or related psychoses - a comparison between different antipsychotic agents", Psychopharmacology, 154, pp.205~212 (2001)
- Wood SC, "Food intake and energy balance in Diabetes Mellitus. 5th Ed", pp.175~192 (1997), Appleton and Lange